Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
253.29
-1.52 (-0.60%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 339.29M EUR in the quarter ending June 30, 2026, with 114.68% growth. This brings the company's revenue in the last twelve months to 1.05B, up 113.35% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
1.05B EUR
Revenue Growth
+113.35%
P/S Ratio
13.91
Revenue / Employee
880,589 EUR
Employees
1,189
Market Cap
16.63B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | 9.05M | 591.57% |
| Dec 31, 2017 | 1.53M | -3.08M | -66.78% |
| Dec 31, 2016 | 4.61M | -3.51M | -43.26% |
| Dec 31, 2015 | 8.12M | -5.87M | -41.94% |
| Dec 31, 2014 | 13.98M | -6.43M | -31.48% |
| Dec 31, 2013 | 20.41M | 4.83M | 30.96% |
| Dec 31, 2012 | 15.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Corcept Therapeutics | 830.81M |
ASND News
- 4 days ago - BMO starts Ascendis at Outperform on further platform growth - TheFly
- 4 days ago - Ascendis Pharma initiated with an Outperform at BMO Capital - TheFly
- 4 days ago - Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients - GlobeNewsWire
- 6 days ago - Ascendis Pharma reports Q2 EPS 90c, consensus 77c - TheFly
- 6 days ago - Ascendis Pharma price target lowered to $329 from $345 at Barclays - TheFly
- 6 days ago - Ascendis Pharma price target raised to $341 from $325 at TD Cowen - TheFly
- 6 days ago - Ascendis Pharma price target raised to $290 from $280 at RBC Capital - TheFly
- 9 days ago - Ascendis Pharma Earnings Call Transcript: Q2 2026 - Transcripts